Radiation guidelines for gliomas

Cancer Radiother. 2022 Feb-Apr;26(1-2):116-128. doi: 10.1016/j.canrad.2021.08.006. Epub 2021 Dec 22.

Abstract

Gliomas are the most frequent primary brain tumour. The proximity of organs at risk, the infiltrating nature, and the radioresistance of gliomas have to be taken into account in the choice of prescribed dose and technique of radiotherapy. The management of glioma patients is based on clinical factors (age, KPS) and tumour characteristics (histology, molecular biology, tumour location), and strongly depends on available and associated treatments, such as surgery, radiation therapy, and chemotherapy. The knowledge of molecular biomarkers is currently essential, they are increasingly evolving as additional factors that facilitate diagnostics and therapeutic decision-making. We present the update of the recommendations of the French society for radiation oncology on the indications and the technical procedures for performing radiation therapy in patients with gliomas.

Keywords: Anaplastic glioma; Biologie moléculaire; Biomarkers; Diffuse glioma; French society for radiation oncology; Glioblastoma; Glioblastome; Gliome anaplasique; Gliome diffus; Radiation therapy; Radiothérapie; Recommandations; Recommendations; Société française de radiothérapie oncologique.

Publication types

  • Practice Guideline

MeSH terms

  • Age Factors
  • Aged
  • Antineoplastic Agents, Alkylating / therapeutic use
  • Biomarkers, Tumor / genetics
  • Brain Neoplasms / diagnostic imaging
  • Brain Neoplasms / genetics
  • Brain Neoplasms / pathology
  • Brain Neoplasms / radiotherapy*
  • Clinical Decision-Making
  • France
  • Glioblastoma / diagnostic imaging
  • Glioblastoma / radiotherapy
  • Glioma / diagnostic imaging
  • Glioma / genetics
  • Glioma / pathology
  • Glioma / radiotherapy*
  • Humans
  • Karnofsky Performance Status
  • Magnetic Resonance Imaging
  • Middle Aged
  • Neoplasm Grading
  • Organs at Risk
  • Radiation Oncology
  • Radiation Tolerance
  • Societies, Medical
  • Temozolomide / therapeutic use

Substances

  • Antineoplastic Agents, Alkylating
  • Biomarkers, Tumor
  • Temozolomide